ReviewExpert review of proteomics2016
Immunocapture strategies in translational proteomics.
Review in Expert review of proteomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Immune profiling of T cells: A comparative analysis of single-cell TCR sequencing using 10X Genomics and Parse Biosciences platforms.Biochemistry and biophysics reports · 2026Article
- Review
- Multiplex quantification of endocrine proteins in volumetric dried blood spots.Clinical proteomics · 2025Article
- Plasma/Serum Proteomics based on Mass Spectrometry.Protein and peptide letters · 2024Review
- Multiplexed selectivity screening of anti-GPCR antibodies.Science advances · 2023Article
- Bioinformatics tools and data resources for assay development of fluid protein biomarkers.Biomarker research · 2022Review
- Deletion of Gremlin-2 alters estrous cyclicity and disrupts female fertility in mice†.Biology of reproduction · 2021Article
- Circulating proteins associated with allergy development in infants-an exploratory analysis.Clinical proteomics · 2021Article
- Affinity-free enrichment and mass spectrometry analysis of the ovarian cancer biomarker CA125 (MUC16) from patient-derived ascites.The Analyst · 2021Article
- Genetics meets proteomics: perspectives for large population-based studies.Nature reviews. Genetics · 2021Review
- Liquid Chromatography-Mass Spectrometry for Clinical Metabolomics: An Overview.Advances in experimental medicine and biology · 2021Article
- Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles.Scientific reports · 2019Article
- Rebooting Human Immunology.Annual review of immunology · 2018Review
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.Alzheimer's research & therapy · 2018Review
- Liquid Chromatography-High Resolution Mass Spectrometry Analysis of Platelet Frataxin as a Protein Biomarker for the Rare Disease Friedreich's Ataxia.Analytical chemistry · 2018Article
- The Human Plasma Proteome Draft of 2017: Building on the Human Plasma PeptideAtlas from Mass Spectrometry and Complementary Assays.Journal of proteome research · 2017Article
- Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI).Journal of visualized experiments : JoVE · 2017Article
- Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with Associations to T-Stage and Recurrence.Translational oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aiming at clinical studies of human diseases, antibody-assisted assays have been applied to biomarker discovery and toward a streamlined translation from patient profiling to assays supporting personalized treatments. In recent years, integrated strategies to couple and combine antibodies with mass spectrometry-based proteomic efforts have emerged, allowing for novel possibilities in basic and clinical research. Described in this review are some of the field's current and emerging immunocapture approaches from an affinity proteomics perspective. Discussed are some of their advantages, pitfalls and opportunities for the next phase in clinical and translational proteomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.